Health Condition 1: O- Medical and Surgical
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: type 1 and 2 DM who require vitrectomy for diabetic TRD willing for preoperative injection of Ranibizumab phakic or pseudophakic willing for follow up period of 3 months
Exclusion criteria
Exclusion criteria: aphakic patients NVI/NVG history of prior vitrectomy combined retinal detachment requiring silicone oil tamponade in case of intraoperative break formation unwilling for preoperative injection of Ranibizumab history of stroke/MI 3 months before injection of Ranibizumab unable to maintain a particular posture after surgery, if required unwilling to be a part of the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| we will compare the incidence of epiretinal membrane formation between group A and group B group A- MIOCT will be used at the end of surgery to look for preretinal residual membranes. They will be removed intraoperatively using MIOCT. group B- conventional ILM peeling groupTimepoint: day 1, 1 week, 1 month and at 3 months. | — |
Secondary
| Measure | Time frame |
|---|---|
| comparison of visual gain and any complications such as postoperative vitreous cavity haemorrhage between the two groupsTimepoint: at 3 months | — |
Countries
India
Contacts
Post graduate institute of medical education and research, Chandigarh